Response to Letter to the Editor From Min Gong et al: "Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis"

J Clin Endocrinol Metab. 2021 Jan 1;106(1):e403. doi: 10.1210/clinem/dgaa446.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Bone Density Conservation Agents* / adverse effects
  • Denosumab / adverse effects
  • Humans
  • Osteoporosis* / drug therapy

Substances

  • Bone Density Conservation Agents
  • Denosumab